Brian Baranick - 25 Feb 2026 Form 4 Insider Report for EXACT SCIENCES CORP (EXAS)

Role
EVP, GM, Precision Oncology
Signature
/s/ Brian Baranick by Mark Busch, attorney-in-fact
Issuer symbol
EXAS
Transactions as of
25 Feb 2026
Net transactions value
$0
Form type
4
Filing time
27 Feb 2026, 16:30:14 UTC
Previous filing
30 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Baranick Brian EVP, GM, Precision Oncology C/O EXACT SCIENCES CORP., 5505 ENDEAVOR LANE, MADISON /s/ Brian Baranick by Mark Busch, attorney-in-fact 27 Feb 2026 0001941313

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding EXAS Common Stock 103,874 25 Feb 2026 Direct F1
holding EXAS Common Stock 795 25 Feb 2026 Held in 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EXAS Restricted Stock Units Award $0 +28,063 $0.000000 28,063 25 Feb 2026 Common Stock 28,063 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 In addition to the shares of Common Stock reported on this Form 4, which total 104,669 shares, Mr. Baranick also holds, in the aggregate, an additional 28,063 restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock.
F2 Each restricted stock unit represents a contingent right to receive one share of common stock.
F3 These restricted stock units vest in four equal annual installments beginning on February 25, 2027.